Concepedia

Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors

Antonio Jimeno, Glen J. Weiss, Wilson H. Miller, Scott Gettinger, Bernhard J. Eigl, Anne Lynn S. Chang, Joi Dunbar, Shannon Devens, Georgios Skliris, Jeff Kutok,

Clinical Cancer Research · 2013 · 168 citations · 21 references

DOIFull text

Open access

Abstract

IPI-926 was well tolerated up to 160 mg QD within 28-day cycles, which was established as the recommended phase II dose and schedule for this agent. Single-agent activity of IPI-926 was observed in HhP inhibitor-naïve patients with BCC.

References

21

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

, , +17

Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer

Kenneth P. Olive, Michael A. Jacobetz, Christian J. Davidson et al. · Science · 2009 · 3.1K citations · Full text

, , +12

Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours

David M. Berman, Sunil Karhadkar, Anirban Maitra et al. · Nature · 2003 · 1.3K citations

, , +10

Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma

Daniel D. Von Hoff, Patricia LoRusso, Charles M. Rudin et al. · New England Journal of Medicine · 2009 · 1.1K citations · Full text

Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer

D. Neil Watkins, David M. Berman, Scott G. Burkholder et al. · Nature · 2003 · 1.1K citations

, , +8